- Mechanism
- Agonizes the ghrelin receptor to stimulate GH/IGF-1 release
- Typical research dose
- 10-25 mg/day oral
- Route
- Oral
- Half-life
- ~24 hours
- Legal status
- Investigational / Research Only
Overview
MK-677 (Ibutamoren) is a potent, orally active non-peptide growth hormone secretagogue that mimics the action of ghrelin. This small molecule binds to the ghrelin receptor to stimulate the release of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) without significantly elevating cortisol levels. Unlike traditional peptides that require injection, this compound boasts high oral bioavailability and a long half-life, allowing for once-daily dosing. Researchers actively study the MK-677 (Ibutamoren) peptide and its analogs for potential applications in treating muscle wasting, bone density loss, and growth hormone deficiency.
Potential Benefits
- Reversal of Catabolism: Clinical data indicates that MK-677 reverses diet-induced nitrogen wasting, suggesting potential for treating muscle catabolism (Murphy et al., 1998).
- Bone Density Support: Oral administration increases markers of bone turnover in elderly adults, highlighting its potential for age-related skeletal fragility (Murphy et al., 1999).
- Body Composition Alteration: Research demonstrates that MK-677 (Ibutamoren) benefits include increased lean body mass and altered circulating biomarkers (Cardaci et al., 2022).
- Somatic Growth Stimulation: Animal models show significant effects on somatic growth, supporting its investigation for pediatric growth hormone deficiencies (Lee et al., 2018).
- Elevated IGF-1 Levels: Clinical trials confirm sustained increases in serum IGF-1 levels across various populations, including those with chronic kidney disease (NCT00395291).
- Sleep Architecture Influence: Clinical observations suggest that growth hormone secretagogues may positively influence sleep architecture and recovery metrics (Sigalos et al., 2018).
Where to Buy MK-677 (Ibutamoren)
Licensed Peptides
View →Research compound. MK-677 (Ibutamoren) is a research chemical, typically not FDA-approved for human consumption. Sale or use for human consumption may be illegal in your jurisdiction.
No compensation. PeptideStack does not endorse, verify, or receive compensation from any vendor. No affiliate or referral relationships.
Verify third-party COAs and consult a qualified healthcare provider before using any compound.
Side Effects
Common side effects:
- Increased appetite (hyperphagia) due to ghrelin receptor agonism
- Transient mild lower extremity edema or water retention
- Lethargy, fatigue, or increased sleepiness
- Mild, transient increases in fasting blood glucose levels
Rare or serious side effects:
- Decreased insulin sensitivity with prolonged, continuous use
- Potential exacerbation of pre-existing heart failure due to fluid retention
- Joint pain or myalgia associated with elevated growth hormone
MK-677 (Ibutamoren) is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
Ghrelin Receptor Agonism drives the primary mechanism of MK-677. This small molecule selectively binds to the growth hormone secretagogue receptor (GHSR) in the pituitary gland and hypothalamus, mimicking the endogenous hormone ghrelin. By activating this pathway, MK-677 stimulates a pulsatile release of growth hormone and subsequently increases systemic insulin-like growth factor 1 (IGF-1) production. This pulsatile release closely mirrors natural physiological secretion patterns, preventing the rapid receptor downregulation often seen with synthetic hormone replacement.
Hormonal Selectivity distinguishes MK-677 from other secretagogues. While it robustly elevates GH and IGF-1, it maintains a highly specific endocrine profile that avoids clinically significant increases in cortisol, prolactin, or luteinizing hormone. This targeted action allows researchers to isolate MK-677 (Ibutamoren) benefits for muscle and bone tissue without triggering widespread hormonal dysregulation.
Origin & History
Discovery and Development of MK-677 originated at Merck & Co. as researchers sought oral alternatives to injectable recombinant human growth hormone. Initially developed in the late 1990s, the compound entered numerous clinical trials targeting conditions like frailty, hip fracture recovery, and fibromyalgia (Adunsky et al., 2011). Researchers also investigated its impact on nonalcoholic fatty liver disease and chronic kidney disease, though some studies were withdrawn or terminated early (NCT01343641). Despite demonstrating efficacy in elevating IGF-1 and reversing catabolism, it did not achieve primary endpoints in certain trials, such as those for Alzheimer's disease progression (Sevigny et al., 2008).
Regulatory Status classifies MK-677 strictly as an investigational new drug rather than an approved therapeutic. It remains heavily utilized in preclinical and clinical research, including ongoing Phase 3 trials for pediatric growth hormone deficiency (NCT06948214). Due to its potent effects on body composition, sports authorities actively monitor it, leading to the development of advanced doping control detection methods for equine and human athletes (Viljanto et al., 2023).